glp 1 neurological effects Neuroprotective of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities Frontiers | GLP-1 Suppresses Feeding

Once blood levels reach steady state through daily dosing, the long half-life of semaglutide (approximately 7 days) means levels do not drop dramatically between doses

A patient may be a candidate for GLP-1 weight loss if they have obesity, overweight with weight-related health concerns, insulin resistance, prediabetes, type 2 diabetes risk, high blood pressure, high cholesterol, fatty liver concerns, sleep apnea risk, or repeated difficulty losing and maintaining weight with lifestyle changes alone

This article is intended for licensed prescribers and healthcare professionals

2010;34 Suppl 1:S47-55

Please get in touch if you need any further advice